射频消融治疗良性甲状腺结节和复发性甲状腺癌的安全性：系统评价和荟萃分析。

Safety of radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: a systematic review and meta-analysis.

机构信息

a Department of Radiology and Research Institute of Radiology , University of Ulsan College of Medicine, Asan Medical Center , Seoul , Republic of Korea.

b Department of Radiology , Namwon Medical Center , Namwon-si , Republic of Korea.

出版信息

Int J Hyperthermia. 2017 Dec;33(8):920-930. doi: 10.1080/02656736.2017.1337936. Epub 2017 Jun 26.

DOI:10.1080/02656736.2017.1337936

PMID:28565997

Abstract

OBJECTIVE

We performed a systematic review and meta-analysis to evaluate the safety of radiofrequency ablation (RFA) for the treatment of benign thyroid nodules and recurrent thyroid cancers.

MATERIALS AND METHODS

Ovid-MEDLINE, EMBASE, and Library of Cochrane databases were searched up to 12 July 2016 for studies on the safety of RFA for treating benign thyroid nodules or recurrent thyroid cancers. Pooled proportions of overall and major complications were assessed using random-effects modelling. Heterogeneity among studies was determined using the χ statistic for the pooled estimates and the inconsistency index I.

RESULTS

A total of 24 eligible studies were included, giving a sample size of 2421 patients and 2786 thyroid nodules. 41 major complications and 48 minor complications of RFA were reported, giving a pooled proportion of 2.38% for overall RFA complications [95% confidence interval (CI): 1.42%-3.34%] and 1.35% for major RFA complications (95% CI: 0.89%-1.81%). There were no heterogeneities in either overall or major complications (I = 1.24%-21.79%). On subgroup analysis, the overall and major complication rates were significantly higher for malignant thyroid nodules than for benign thyroid nodules (p = 0.0011 and 0.0038, respectively).

CONCLUSIONS

RFA was found to be safe for the treatment of benign thyroid nodules and recurrent thyroid cancers.

摘要

目的

我们进行了一项系统评价和荟萃分析，以评估射频消融（RFA）治疗良性甲状腺结节和复发性甲状腺癌的安全性。

材料与方法

检索 Ovid-MEDLINE、EMBASE 和 Cochrane 图书馆数据库，截至 2016 年 7 月 12 日，检索关于 RFA 治疗良性甲状腺结节或复发性甲状腺癌安全性的研究。使用随机效应模型评估总体和主要并发症的合并比例。使用合并估计值的 χ 统计量和不一致性指数 I 来确定研究之间的异质性。

结果

共纳入 24 项符合条件的研究，纳入了 2421 例患者和 2786 个甲状腺结节。报道了 RFA 的 41 例主要并发症和 48 例次要并发症，总体 RFA 并发症的合并比例为 2.38%（95%可信区间：1.42%-3.34%），主要 RFA 并发症的合并比例为 1.35%（95%可信区间：0.89%-1.81%）。总体和主要并发症均无异质性（I=1.24%-21.79%）。亚组分析显示，恶性甲状腺结节的总体和主要并发症发生率明显高于良性甲状腺结节（p=0.0011 和 0.0038）。